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The Swedish Lucentis Quality Registry is a 12-month, open-label, observational, prospective, and retrospective study of
ranibizumab administration for wet AMD. Visual acuity (VA) was measured with Snellen or ETDRS chart in 370 patients (66.8%
women; age range 46–93 years). In total, a mean of 4.7 ± 1.6 injections per patient (range 1–10) was given to month 12. Mean VA
score was 58.3 ± 12.2 letters before treatment, 63.3 ± 12.5a f t e r3i n j e c t i o n s( Δ4.9 ± 10.1 letters from baseline), and 59.3 ± 16.2a t
12 months (Δ1.0 ± 13.6). VA score from baseline to month 12 was stable in 74.4% of patients, improved by 15 letters/3 lines or
more in 14.7%, and decreased by ≥15 letters/3 lines in 10.9% of patients. With a mean of 4.7 ranibizumab injections per patient
per year, mean VA was stabilised but not increased. To maintain the initial gain seen after the ﬁrst three injections, an average of
1.8 ±1.5 additional injections does not appear to be adequate.
1.Introduction
As the population ages, establishing eﬀective treatment
strategies for age-related macular degeneration (AMD)
becomes increasingly important. AMD is the leading cause
of irreversible blindness in patients over the age of 50 [1–
3], with an incidence that rises from 0.2% in those aged 55–
64 to 13% after the age of 85 [4]. The neovascular form
of AMD, characterised by choroidal neovascularisation and
proliferation of ﬁbrous tissue, represents only 10–15% of
cases but is responsible for more than 80% of AMD-related
severe visual loss or blindness [5].
Management of neovascular AMD centres on intravitreal
antiangiogenic therapy, which localises therapy to the eye
andavoidssystemicexposure.Followinglimitedsuccesswith
pegaptanib, the ﬁrst licensed intravitreal agent for neovas-
cular AMD [6], ranibizumab, became available in 2006.
Ranibizumab is an antivascular endothelial growth factor
(VEGF) antibody fragment which binds to VEGF and
inhibits the contribution of VEGF to the formation of
neovascular lesions in the choroid [7]. Two pivotal trials in
which ranibizumab was injected intravitreally once a month,
one placebo-controlled and the other using Photodynamic
Therapy (PDT) as the control, both showed a remarkable
improvement in visual acuity (VA) from baseline in treated
eyes, as measured by the Early Treatment Diabetic Retinopa-
thy Study (ETDRS) chart [8, 9]. On the basis of these results,
ranibizumabisnowrecommendedasaﬁrst-linetherapy[10]
and is the most widely prescribed treatment for neovascular
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Nevertheless, there remain unanswered questions
about the optimal evaluation and treatment regimen for
ranibizumabthatbalancesVAimprovementintheindividual
patient versus logistical and cost issues. Recommendations
for the use of ranibizumab have been developed which
point out that continued monthly injections oﬀer the best
VA outcomes but that if regular monthly administration is
not feasible then ﬂexible retreatment after three monthly
injections is viable [11]. In practice, however, the current
consensus is that after the ﬁrst three injections, monthly
maintenance visits with clinician-determined retreatment
are appropriate [10, 12]. Evidence concerning the eﬃcacy
of administering ranibizumab as needed based on monthly
evaluation by clinical ﬁndings or imaging is growing, with
two small, nonrandomised prospective studies [13, 14], a
series of retrospective analyses [15–21] and most recently a
large multicentre, single-blind trial [22].
As part of an ongoing pharmacovigilance program for
ranibizumab, Novartis Pharma AG (Basel, Switzerland) has
initiated the LUMINOUS program designed to assess long-
term safety, eﬃcacy, treatment patterns, and health-related
quality of life outcomes in a large number of patients
treated with ranibizumab in routine clinical practice across
the world. We report here the ﬁndings from the Swedish
Lucentis Quality Registry, which records eﬃcacy and safety
results following ranibizumab administration according to
local practice in patients with AMD at ﬁve specialist centres.
The aim of the registry is to understand how ranibizumab
is being deployed in routine practice outside the setting
of a clinical trial, and to establish what improvement in
VA can be achieved and the number of injections and
visits needed. The current paper addresses the following
objectives of the registry: (i) to characterise the population
of patients receiving ranibizumab, (ii) to record the number
of injections administered and the dosing frequency, (iii)
to evaluate the eﬀect of ranibizumab treatment on VA, and
(iv) to characterise, describe, and evaluate side eﬀects. Data
collected up to January 2011 are presented.
2. Methods
2.1. Study Design. The Swedish Lucentis Quality Registry
is a 12-month, open-label, observational, noncomparative
study that is ongoing at ﬁve specialist centres in Sweden.
These clinics were chosen since they were among the ﬁrst to
implement intravitreal ranibizumab treatment for wet AMD
in Sweden. Outpatients who were receiving ranibizumab
at the time the study started (retrospective component) or
with whom the decision was subsequently made to start
treatment with ranibizumab (prospective component) were
eligible for inclusion unless they were receiving the drug
within a controlled clinical trial. Ranibizumab treatment
is administered according to the approved label, that is,
three initial injections and then according to need based on
VA, optical coherence tomography (OCT) ﬁndings, and the
investigator’s judgment. The assessments performed and the
criteria applied at each centre to initiate treatment or rein-
jection were not recorded. Standard single-use ranibizumab
vials (containing 0.23mL ranibizumab 10mg/mL) are used.
Retrospective data were collected from patients who
started ranibizumab during the period from July 2007 to
March 2008. The prospective component was initiated in
April 2008, when the registry was opened, with recruitment
ending in December 2009. Written, informed consent was
obtained from all participants following ethical approval
from the Regional Ethical Review Board in Stockholm.
2.2. Evaluation and Data Collection. All clinical assessments
areperformedatthediscretionoftheinvestigatorasperlocal
practice. Data are recorded at every monthly visit during
the ﬁrst 12 months of treatment. For both retrospectively
and prospectively included patients, the visits that took
place closest to these times were used for evaluation.
Retrospective data were obtained from patients’ medical
records. Prospective data are collected at study entry (i.e., the
date of ﬁrst ranibizumab injection) and during the following
year, in accordance with the local visit schedule.
The following data are obtained at baseline and at all
routine visits during the ﬁrst year of ranibizumab treatment:
patient age and gender (baseline only); indication for use
of ranibizumab; cause of treatment discontinuation prior to
the end of the 12-month observation, if applicable; number,
timing, and frequency of ranibizumab doses administered
during the ﬁrst 12 months of treatment; whether OCT was
or was not performed at baseline; VA prior to treatment
and at all visits (except at the second and third injection
visits when VA was not always measured) during the ﬁrst
12 months of treatment as assessed by the ETDRS chart
and adverse events since study entry. In addition, vision-
r e l a t e df u n c t i o na sm e a s u r e db yT h eN a t i o n a lE y eI n s t i t u t e
Visual Function Questionnaire-25 (VFQ-25) is recorded at
study entry, 3 months and 12 months in the prospectively
recruited patients. VFQ-25 subscales were calculated as per
the recommended procedure [23]. Each item was converted
to a 0-to-100 scale where higher scores represent better
functioning. Items within a subscale were averaged and the
score represents the average for all items in the subscale. The
overall score was averaged over all subscales, excluding the
general health item, and thus equal weight was given to each
subscale.
All data are entered online by the clinical team at
each centre to a password-protected web-based data system.
Access to individual patient data is only available to the local
clinical team. All participating centres have online access to
pooled data in real time from their own centre and from the
total patient population.
2.3. Data Analysis. Assessment of eﬃcacy is based on
VA measurements (ETDRS chart scores) before and after
treatment. In 100 of the retrospective patients, Snellen
VA testing was used at baseline. In order to use these
data, the Snellen value was recalculated to determine the
corresponding ETDRS value using a formula that reﬂects the
relationship between the two methods:
ETDRS (number of letters) = 50
∗log10

Snellen
100

+3 6 .
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VAmeasurementsarepresentedasabsolutevalues(mean
± standard deviation [SD]), as a mean change from baseline
to month 12 (mean ± s t a n d a r de r r o r[ S E M ] ) ,a n di nt e r m s
of the number of patients with (i) a gain of ≥15 letters or 3
lines, (ii) a change of <15 letters or 3 lines, or (iii) a loss of
≥15 letters or 3 lines.
The VFQ-25 subscales are not strictly ordinal or equal
interval measures, but because they approximate interval-
level measures, mean and standard deviations were com-
puted [24]. Change from baseline to 3 and 12 months was
tested with Wilcoxon signed rank test. Since the probability
of making type 1 error increases with the number of analyt-
ical tests performed, care should be taken when interpreting
the results.
Safety assessment was based on the frequency of adverse
events and serious adverse events. Adverse events were
categorised by severity (mild, moderate, or severe), relation-
ship to ranibizumab (probable, possible, or unlikely), and
whether they constituted a serious adverse event.
Data are presented for the on-treatment population,
comprising all intent-to-treat (ITT) patients in whom treat-
ment/followup visits were not discontinued during the one-
year study period. All data are presented descriptively.
It was anticipated that retrospective data from approxi-
mately 200 patients would be available, with prospective data
from a further 200 patients. No sample size calculation was
required since no statistical hypothesis was tested.
The study database and electronic data capture were
managed by Pharma Consulting Group AB, Uppsala, Swe-
den.DataanalysiswasundertakenbythePharmaConsulting
Group using the SAS system version 9.2 (SAS Institute Inc,
Cary, NC, USA).
3. Results
3.1. Patient Population. In total, 475 patients were enrolled
in the registry, of whom 471 received at least one dose of
ranibizumab and formed the ITT population. Two hun-
dred and seventy-two patients were enrolled retrospectively
[57.7%] and 199 prospectively [42.3%]. Of these, 370
patients were followed for one year without discontinuing
ranibizumab treatment/followup visits (the “on-treatment”
population; retrospective 206 [55.7%], prospective 164
[44.3%]). In total, 101/471 patients (21.4%) discontinued
before one year. In approximately a third of these cases (n =
34), this was due to the treating physician’s decision that
no further followup was required (Table 1). The 43 patients
who discontinued for “other reasons” did so for a variety of
causes, the most frequent being VA was too low (n = 17),
lack of VA improvement (n = 3), nonattendance at followup
visits (n = 7), change in therapy (n = 6), death (n = 5), and
various reasons (n = 5). There were no marked diﬀerences
between the ITT and on-treatment populations in terms of
demographics or baseline characteristics (Table 1).
Two-thirds of the population were female, and the mean
age at entry was 78 years (Table 1). Ranibizumab injections
were evenly divided between left and right eyes (52.7% and
47.3%,resp.).Themeannumberofvisitsduringtheﬁrstyear
of treatment in the on-treatment population, irrespective of
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Figure 1: Number of ranibizumab injections received during year
1 in the retrospectively and prospectively recruited subpopulations
(on-treatment population, n = 370).
whether ranibizumab was injected, was 9.4 ± 1.8, ranging
from 4 to 13 visits. The last visit at which VA was assessed
occurred at months 7, 8, 9, 10, 11, 12, and 13 in 1, 6, 22, 27,
50, 262, and 2 patients, respectively.
3.2. Ranibizumab Therapy. All three initial ranibizumab
injections were administered to 95.1% (352/370) in the on-
treatment population. The mean number of ranibizumab
injections was 4.7±1.6( m e a n1 .8±1.5 after the three initial
injections). The number of injections in the on-treatment
population was similar in the retrospective subpopulation
(mean 4.6 ± 1.5; 197/206 [95.6%] received all three initial
injections) and the prospective subpopulation (mean 4.9 ±
1.6; 155/164 [94.5%]). The majority of patients received
three (27.6%, n = 102), four (22.4%, n = 83), or ﬁve
(18.6%, n = 69) injections, with a slightly higher proportion
of prospectively enrolled patients receiving more than three
injections than in the earlier, retrospective cohort (Figure 1).
There was no correlation between VA at baseline and the
number of ranibizumab injections given (data not shown).
3.3. Visual Acuity. The mean VA score at baseline was 58.3 ±
12.2 letters (on-treatment population) and was similar in the
retrospective and prospective subpopulations (58.2 ± 12.0
letters and 58.4 ± 12.3 letters, resp.). At month 12, the
mean VA score was 59.3 ± 16.2 letters, an increase of 1.0 ±
13.6 versus baseline. The maximum improvement was seen
at month 3 following administration of three ranibizumab
injections, when mean VA score peaked at 63.3±12.5l e t t e r s ,
a mean increase of 4.9 ± 10.1 from baseline. After month 3,
the mean VA score progressively declined back to baseline
levels (Figure 2). The mean improvement in VA score from
baseline to month 12 was greater in younger patients and
in females (Table 2). There was no consistent association
between improvement in VA score and the number of
injections administered.
The majority of patients (74.4%) showed a stable score
over the 12-month period, deﬁned as a change of <154 Journal of Ophthalmology
Table 1: Baseline characteristics and ranibizumab treatment.
ITT population
(n = 471)
On-treatment population
(n = 370)
Baseline age (years)
Mean ±SD 78.1 ±8.07 7 .7 ±8.0
Range 46–93 46–93
Gender, n (%)
Male 160 (34.0%) 123 (33.2%)
Female 311 (66.0%) 247 (66.8%)
Indication for ranibizumab, n (%)
Wet AMD 468 (99.4%) 368 (99.5%)
Other 3 (0.6%) 2 (0.5%)
Baseline OCT performed, n (%)
Yes 357 (75%) 242 (75%)
No 115 (24%) 82 (25%)
Unknown 2 (0.4%) 0
Baseline ETDRS, n (%)
Yes 337 (71%) 223 (69%)
No 136 (28.6%) 101 (31%)
Unknown 2 (0.4%) 0
Initial 3 ranibizumab injections, n (%)
No
1 11 (2.3%) 3 (0.8%)
2 25 (5.3%) 15 (4.1%)
Yes 435 (92.4%) 352 (95.1%)
Total number of ranibizumab injections (≤12 months) (12 months)
Mean ±SD 4.4 ±1.64 .7 ±1.6
Range 0–10 1–10
Number of visits (≤12 months) (12 months)
Mean ±SD 9.4 ± 2.6 10.3 ±1.8
Range 1–14 5–14
Discontinuation before month 12, n (%) 101 (21.4%)
Reason for discontinuation, n (%)
Withdrawal of informed consent 2 (0.4%) —
Decline further injections 6 (1.2%) —
Serious complication 1 (0.2%) —
Retinal detachment 0—
Referred for continuous follow up 7 (1.5%) —
Physician’s decision that no further 34 (7.2%) —
followup is necessary
Other reason 43 (9.1%) —
Unknown 8 (1.7%) —
letters/3 lines. In total, 14.7% (n = 54) had improved by 15
letters/3 lines or more, while 10.9% of patients (n = 40) had
lost ≥15 letters/3 lines (Table 2).
3.4. Vision-Related Function (VFQ-25). The increase in VA
at month 3 was accompanied by a signiﬁcant improvement
in VFQ-25 total score from baseline, as recorded in 131 of
the prospectively recruited patients (Table 3). Several VFQ-
25 subscales, including general vision, ocular pain, and both
near and distance activities, also improved signiﬁcantly. By
month 12, the general vision, near activities, and driving
subscales were signiﬁcantly higher compared to baseline, but
total VFQ-25 score had returned to near-baseline levels.
3.5. Safety and Tolerability. In the ITT population, that is, all
patients who received one or more ranibizumab injection,
a total of 17 adverse events occurred in 16 patients during
followup (16/471 [3.4%]). Of these, eight were gradedJournal of Ophthalmology 5
Table 2: Change in VA score from baseline to last visit (on-treatment population, n = 370†).
VA at baseline
mean ±SD
median (range)
VA at last visit
mean ±SD
median (range)
Change from
baseline to last visit
mean ±SD
median (range)
Improved
(change ≥15
letters/3 lines)
N (%)
Stable
(change <15
letters/3 lines)
N (%)
Deterioration
(change ≥15
letters/3 lines)
N (%)
All patients 58.3 ±12.2
60 (7–86)
59.3 ±16.2
61 (1–90)
1.0 ±13.6
1( −38–56) 54 (14.7%) 273 (74.4%) 40 (10.9%)
<80 years (N = 195) 59.6 ±11.1
60 (30–85)
61.6 ±14.8
63 (16–90)
2.1 ±12.8
3( −37–36) 33 (16.9%) 146 (74.9%) 16 (8.2%)
≥80 years (N = 172) 56.8 ±13.1
60 (7–86)
56.6 ±17.3
59 (1–88)
−0.2 ±14.5
0( −38–56) 21 (12.2%) 127 (73.8%) 24 (14.0%)
Female (N = 245) 58.5 ±11.6
60 (17–86)
60.3 ±14.8
62 (1–88)
1.9 ±12.4
3( −38–39) 35 (14.3%) 190 (77.6%) 20 (8.2%)
Male (N = 122) 57.9 ±13.2
60 (7–85)
57.2 ±18.7
60 (5–90)
−0.7 ±15.7
0( −38–56) 19 (15.6%) 83 (68.0%) 20 (16.4%)
Baseline VA ≤ median
(N = 179)
48.2 ±8.3
50 (7–59)
51.8 ±16.2
53 (1–83)
3.5 ±15.2
4( −37–56) 40 (22.3%) 120 (67.0%) 19 (10.6%)
Baseline VA > median
(N = 188)
67.8 ±6.0
67 (60–86)
66.4 ±12.7
69 (23–90)
−1.4 ±11.5
−1( −38–21) 14 (7.4%) 153 (81.4%) 21 (11.2%)
Retrospectively recruited
(N = 203)
58.2 ±12.0
60 (7–86)
60.1 ±15.6
61 (5–88)
1.9 ±13.5
2( −37–56) 32 (15.8%) 153 (75.4%) 18 (8.9%)
Prospectively recruited
(N = 164)
58.4 ±12.3
60 (21–84)
58.3 ±17.0
61 (1–90)
−0.1 ±13.7
0.5 (−38–33) 22 (13.4%) 120 (73.2%) 22 (13.4%)
†Data not available for 3 patients.
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Figure 2: Change in VA score (ETDRS chart) from baseline (BL) to
month 12 (on-treatment population, n = 370). Values are shown as
mean ±SEM.
mild (pain (2), conjunctivitis (2), retinal pigment epithelial
tear, conjunctival haemorrhage, blepharal papilloma, and
transient ischaemic attack), four moderate (retinal pigment
epithelial tear (2), angina pectoris, and cardiac failure), and
four severe (duodenal ulcer haemorrhage, cerebrovascular
accident, mesothelioma, and death). The treating physician
considered there to be a probable relation to ranibizumab
in two cases (mild conjunctival haemorrhage that did not
require treatment and retinal pigment epithelial tear in a
patient with very low VA before treatment and after one
injection the treatment was stopped due to low vision), and a
possible relation in ﬁve cases: mild pain (2), cerebrovascular
accident, transient ischaemic attack, and retinal pigment
epithelial tear (following which ranibizumab treatment was
temporarily stopped). There were four deaths during the
study, none reported as related to the treatment.
4. Discussion
The Swedish Lucentis Quality Registry provides a large
database relating to clinical experience with ranibizumab
treatment for neovascular AMD, for which almost half the
patients were recruited prospectively. In this cohort of 370
patients followed for one year at ﬁve centres, almost all
patients (95%) received three initial monthly injections as
per the product license, with an average of 1.8 subsequent
injections.TheimprovementinVAfollowingtheinitialthree
injections (mean 4.9 letters) was somewhat lower than that
observed in the pivotal MARINA [8] and ANCHOR [25]
trials (∼6a n d∼10 letters, resp.). With the current treatment
pattern,thisbeneﬁtwasnotsustained:theVAscoreatmonth
12 was similar to baseline.
However, a higher rate of subsequent ranibizumab
injections could be expected to have sustained the initial
improvement in VA seen after the ﬁrst three administrations.
VEGF level has been shown to correlate with the extent of
macular oedema [26], and while the decrease in VEGF level
observed following intravitreal injection of ranibizumab is
lost after four weeks it is prolonged by retreatment [26]. In
the 24-month MARINA [8] and ANCHOR [9, 25] studies,
a ﬁxed monthly schedule of ranibizumab showed sustained
beneﬁtstotheendofeachtrial.Inanattempttominimisethe
number of injections administered, a quarterly ranibizumab
treatment regimen has been investigated in randomised
studies [27–30] but using this approach the sustained6 Journal of Ophthalmology
Table 3: VFQ-25 subscale and total scores at 3 and 12 months. Values are shown as mean ± SD.
Subscale Month 3 Month 12
n Baseline Month 3 P-value† n Baseline Month 12 P-value†
General health 130 52.5 ±21.85 1 .9 ±20.6 0.718 89 53.9 ±23.55 2 .0 ±23.0 0.404
General vision 129 51.0 ±19.85 9 .2 ±18.3 <0.001 89 52.1 ±19.76 0 .2 ±18.7 <0.001
Ocular pain 131 80.0 ±21.88 5 .0 ±17.6 0.001 91 81.7 ±21.18 5 .7 ±17.0 0.081
Near activities 131 58.9 ±18.76 3 .2 ±19.0 <0.001 91 60.2 ±18.66 4 .3 ±19.7 0.029
Distance activities 131 64.4 ±20.36 6 .7 ±20.1 0.026 91 66.8 ±18.86 8 .1 ±20.1 0.435
Vision speciﬁc:
Social functioning 130 79.5 ±21.88 0 .9 ± 19.8 0.213 90 82.1 ±19.78 2 .0 ±18.5 0.760
Mental health 131 59.6 ±28.76 5 .7 ±27.9 <0.001 91 61.9 ±27.36 6 .0 ±28.3 0.055
Role diﬃculties 129 61.7 ±29.56 2 .7 ±29.3 0.720 89 64.9 ±28.76 3 .8 ±28.6 0.636
Dependency 128 74.8 ±31.77 5 .6 ±31.6 0.439 89 79.6 ±30.57 5 .8 ±31.7 0.152
Driving 65 60.7 ±33.86 1 .1 ±35.6 0.897 47 63.3 ±30.25 7 .6 ±31.8 0.044
Colour vision 124 82.9 ±19.98 3 .7 ±20.1 0.568 86 83.5 ±18.78 1 .9 ±19.1 0.328
Peripheral vision 125 70.6 ±20.67 2 .3 ±21.1 0.153 85 72.2 ±19.07 2 .2 ±21.2 0.884
VFQ-25 total 131 67.4 ± 19.3 70.6 ± 19.0 <0.001 91 69.9 ± 17.8 70.9 ± 18.4 0.389
†Wilcoxon signed rank test.
improvement in VA achieved with three monthly injections
was lost. An individualised dosing strategy has been explored
in a small nonrandomised, open-label trial (PrONTO)
[13] which employed three initial monthly injections of
ranibizumabwithsubsequentinjectionsperformedbasedon
the evolution of VA and the presence or absence of subfoveal
ﬂuid, as detected by OCT. The mean VA improvement
described in the PrONTO study was similar to that seen
in the MARINA and ANCHOR trials, but required an
average of 5.6 injections over the ﬁrst year [13], with
the improvement maintained at two years [31]. Another
nonrandomisedprospectivestudy,inwhichpatientsreceived
a mean of 5.1 clinically determined ranibizumab injections
over 12 months, with a single application of reduced ﬂuence
photodynamic therapy, reported a mean VA improvement
o f7 . 2l e t t e r sa tm o n t h1 2[ 14]. Other recent studies have
demonstrated a higher response as the number of injections
increases [21, 32]. The most conclusive evidence comes from
the recent CATT trial, a large randomised study in which
ranibizumab given monthly or as needed was compared
to bevacizumab, again administered monthly or as needed
on the basis of monthly evaluations [22]. Results showed
that the eﬃcacy of ranibizumab at one year, as measured
by improvement in VA, was similar with either monthly
or individualised dosing, with the individualised group
receiving a mean of 6.9 injections by month 12. In our
observational study, a mean of 4.7 injections resulted in sta-
ble VA with no long-term improvement although elsewhere
an individualised, clinically driven approach to reinjection
has demonstrated good results obtained with a mean of >5
reinjections after the initial three-injection regimen [29, 33,
34].Itappearsthatthenumberofreinjectionsmaybecritical
in maintaining early increase in VA and that fewer than 5
injections during the ﬁrst year appear inadequate.
No marked diﬀerence in the change in VA score was ob-
served between the retrospective and prospective subpopula-
tions(tobeconﬁrmed),althoughslightlymoreprospectively
recruited patients received >3 injections. One hundred of the
272 patients in the retrospective population had baseline VA
measuredbySnellenscoring,requiringconversiontoEDTRS
values. The two scoring systems are known to show diﬀer-
ences, particularly in patients with wet AMD and poor VA
[35], but the similarity of VA score at baseline in the retro-
spective cohort (including patients converted from Snellen
scores) and the prospective arm suggests that this was not an
important source of bias.
ThechangeinVAscoreoverthe12-monthfollowupperi-
od was mirrored in the observed change in vision-related
function. A signiﬁcant improvement in VFQ-25 total score
was achieved at month 3 but declined to near-baseline levels
by month 12. Certain subscale scores remained signiﬁcant at
month 12, including general vision and near activities, but
the relatively small number of patients (∼90) and the subjec-
tive nature of scales of this type mean that this should be
interpreted with caution when the improvement in the more
robustendpointofVAscorewasnotmaintainedtomonth12.
Regarding safety, intravitreal ranibizumab has previously
been established as a safe and well-tolerated therapy for
neovascular AMD [36]. In our population of 471 patients,
there were only two adverse events with a probable relation
to ranibizumab (a mild conjunctival haemorrhage and a
pigment epithelium rift) over the 12-month study period,
with a possible relation in a further ﬁve cases. No patient dis-
continuedtreatmentduetoadverseevents.Thissafetyproﬁle
is consistent with the extremely low systemic exposure to
ranibizumab observed following intravitreal administration
and the short half-life of the drug [37, 38], which minimises
the risk of systemic anti-VEGF adverse events.
5. Conclusion
The ﬁndings from this large cohort of retrospectively and
prospectively recruited patients indicate that an individu-
alised approach, whereby three monthly initial injections areJournal of Ophthalmology 7
followed by additional injections as determined by OCT or
clinical monitoring, can maintain VA at long-term baseline
levels. To sustain the short-term improvement seen after
the initial injection schedule, however, requires more than
the mean of 1.8 repeat injections administered in this
population. The observational nature of the study does not,
however, permit speciﬁc recommendations on the optimal
number or frequency of injections or the indications for
reinjection.
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